Can't find what you're looking for? Contact Us!

You have no items in your shopping cart.


Product:

EUFLEXXA®

Manufacturer: Ferring
Active Substance(s) : Sodium hyaluronate
Strength: 10mg/ml
Pack Size: 3-2ml prefilled syringes
Accessories: Package insert
 
 
 
 
Product: EUFLEXXA® Canadian pkg
Manufacturer: Ferring
Active Substance(s) : Sodium hyaluronate
Strength: 10mg/ml
Pack Size: 3-2ml prefilled syringes
Accessories: Package insert
 
 
 
 

Product Specification

Euflexxa is an orthopedic injection indicated for knee pain associated with osteoarthritis. Sourced from a non-avian origin, the sodium hyaluronate in Euflexxa is purified and unlikely to cause allergy. The injection has been scientifically proven to slow the progression of knee pain in osteoarthritis, delaying the need for invasive knee replacement surgery. The knee injection, which is supplied as three 2ml prefilled syringes, comes with a product insert.

What Euflexxa is formulated to do

Euflexxa orthopedic injections are indicated for unresolved knee pain in osteoarthritis patients. It is designed for patients who respond inadequately to pharmacological pain management (such as acetaminophen or other oral analgesics) and physiotherapy.

Fortified with highly potent hyaluronic acid, the injection replenishes degraded synovial fluid to restore its cushioning and lubricating properties. As the friction between bones decreases, knee pain is reduced. By exerting protective actions on the joint, the orthopedic injection dramatically improves joint function and mobility. This ultimately enhances patient’s quality of life.

Euflexxa is associated with a lower risk of allergic reaction, thanks to the highly-purified hyaluronic acid that it is formulated with. In contrast to other orthopedic treatments, the hyaluronic acid in Euflexxa is not obtained from rooster combs, making it suitable for patients with allergy to feathers and birds.

Manufacturer

Euflexxa orthopedic injection is manufactured by Ferring B.V. Since its inception, the company has been leading the pharmaceutical industry, constantly developing innovative pharmaceutics for medical use. The company produces a wide range of products, encompassing areas like osteoarthritis, gastroenterology, obstetrics, endocrinology and infertility. Through ground-breaking research, Ferring B.V. has enhanced the lives of patients around the world. The company is a subsidiary of Ferring Holding SA.

Origin

Euflexxa is developed by Ferring B.V., a pharmaceutical company based in Netherlands.

What else you need to know

As opposed to other orthopedic injections on the market, the active ingredients in Euflexxa injection are obtained from a non-avain source. As a result, the injection has a significantly lower risk of allergy. Formulated using biodegradable ingredients, the orthopedic injection is approved for the treatment of osteoarthritis pain. Although relatively rare, the knee injections may cause nausea, hypertension, arthralgia, back pain, effusion and swelling of the joint. These symptoms are usually short-lived and mild. While the injection procedure is minimally invasive, it may result in injection-site swelling, erythema and itching.

Suggested Usage

  • Inject the content of the syringe intra-articularly into the synovial fluid in the joint. Injection must be performed using aseptic technique. Discard used needle and syringe. Do not reuse them.
  • A full treatment consists of three injections, which are injected weekly for three consecutive weeks.

Composition

Each Euflexxa injection contains 10mg/ml of sodium hyaluronate (a sodium salt of hyaluronic acid). Derived from a non-animal source, the hyaluronic acid used in the orthopedic injection is highly purified and has a high molecular weight. Hyaluronic acid is an element abundant in skin and cartilage. It protects the joints through its cushioning and lubricating actions. However, in disease state, the protective effects of synovial fluid is lost as it becomes diluted. Acting as a visco-supplement, sodium hyaluronate replenishes the degraded synovial fluid, restoring its lubricating and shock-absorbing ability. As the friction between bones decreases, knee pain subsides.

What is in the box

  • Three  2ml  pre-filled syringes (formulated with purified non-animal hyaluronic acid which acts as visco-supplement)
  • Product leaflet (contains important information about the injection, e.g. potential adverse events, precautions, indications, administration method and contraindications)
  • Needles are not included (use a needle of 17 to 21G for administration)

Duration of effect

Thanks to its unique formulation, Euflexxa provides durable pain relief for about six months. However, individual results may vary. While some patients experience pain relief after the first injection, it takes two or all three injections for others to receive adequate analgesia for knee pain.

Storage conditions

Keep Euflexxa injections at a cool, dark place. Store them at a temperature of 15 to 25℃ .

Expiry (shelf life) 

  • Euflexxa injection has a shelf life of three years. Improper storage practice may accelerate the degradation of active ingredient in Euflexxa, rendering it unusable before expiry date.
  • Do not use the injection if the packaging is damaged, as the product is no longer sterile.

People who bought EUFLEXXA® Europe also bought this

  • SYNVISC ONE®

    SYNVISC ONE®

    from $339.00 USD

    SYNVISC ONE®

    from $339.00 USD
  • ORTHOVISC®

    ORTHOVISC®

    from $52.00 USD

    ORTHOVISC®

    from $52.00 USD

  • Disclaimer: Raskel Medical offers only genuine products made by their original manufacturer. All brands are trademarks of their respective owners. Raskel Medical is not operated by, supported by, or affiliated with the manufacturer in any way. Product packaging may not be exactly as shown.